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Abstract
Glucagon-like peptide-1 (GLP-1) is an incretin hormone increasing postpran-
dial insulin release. GLP-1 also induces diuresis and natriuresis in humans
and rodents. The GLP-1 receptor is extensively expressed in the renal vascular
tree in normotensive rats where acute GLP-1 treatment leads to increased
mean arterial pressure (MAP) and increased renal blood flow (RBF). In hyper-
tensive animal models, GLP-1 has been reported both to increase and decrease
MAP. The aim of this study was to examine expression of renal GLP-1 recep-
tors in spontaneously hypertensive rats (SHR) and to assess the effect of acute
intrarenal infusion of GLP-1. We hypothesized that GLP-1 would increase
diuresis and natriuresis and reduce MAP in SHR. Immunohistochemical stain-
ing and in situ hybridization for the GLP-1 receptor were used to localize
GLP-1 receptors in the kidney. Sevoflurane-anesthetized normotensive
Sprague–Dawley rats and SHR received a 20 min intrarenal infusion of GLP-1
and changes in MAP, RBF, heart rate, dieresis, and natriuresis were measured.
The vasodilatory effect of GLP-1 was assessed in isolated interlobar arteries
from normo- and hypertensive rats. We found no expression of GLP-1 recep-
tors in the kidney from SHR. However, acute intrarenal infusion of GLP-1
increased MAP, RBF, dieresis, and natriuresis without affecting heart rate in
both rat strains. These results suggest that the acute renal effects of GLP-1 in
SHR are caused either by extrarenal GLP-1 receptors activating other mecha-
nisms (e.g., insulin) to induce the renal changes observed or possibly by an
alternative renal GLP-1 receptor.
Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic disease
which has been declared a global epidemic and the num-
ber of patients is increasing. T2DM is often associated
with hypertension and both are leading causes in the
development of renal failure (Emdin et al. 2015).
Glucagon-like peptide-1 (GLP-1) is an incretin hor-
mone secreted from enteroendocrine L-cells in the small
intestine. GLP-1 enhances the postprandial insulin release.
GLP-1 is secreted as the active intact GLP-1 (7–36)
amide, but is rapidly degraded to GLP-1 (9–36) amide by
the ubiquitously expressed enzyme dipeptidyl peptidase-4
(DPP-4). This results in a very short in vivo half-life of
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
2017 | Vol. 5 | Iss. 23 | e13503
Page 1
Physiological Reports ISSN 2051-817X
active GLP-1 (Deacon et al. 1995). Besides affecting the
pancreas, GLP-1 has a range of extrapancreatic effects
including effects in the kidneys and the cardiovascular
system (Nauck et al. 2017). It has been demonstrated that
GLP-1 affects blood pressure and renal blood flow (RBF)
along with increases in diuresis and natriuresis (Moreno
et al. 2002; Gutzwiller et al. 2004; Ban et al. 2008; Cra-
joinas et al. 2011; Jensen et al. 2015). When used chroni-
cally, incretin-based treatment is suggested to decrease
blood pressure in both healthy and diabetic humans
(Mistry et al. 2008; Okerson et al. 2010; Wang et al.
2013), although some studies showed no significant effect
on blood pressure (Imamura et al. 2013; Skov et al. 2013;
Asmar et al. 2015). In rodents, the GLP-1-mediated renal
and cardiovascular effects seem to depend on the animal
model used. In salt-sensitive Dahl rats fed a high salt diet,
GLP-1 reduced blood pressure and albuminuria, and
increased Na+ excretion (Yu et al. 2003). The GLP-1
receptor agonist exendin-4 inhibited the development of
hypertension in salt-sensitive obese db/db mice (Hirata
et al. 2009). In spontaneously hypertensive rats (SHR),
DPP-4 inhibition either increased (Jackson et al. 2015) or
decreased blood pressure (Liu et al. 2012), whereas native
GLP-1 was shown not to affect blood pressure (Savignano
et al. 2017). DPP-4 inhibition decreased blood pressure in
diabetic Zucker rats (Aroor et al. 2013). Thus, in hyper-
tensive animal models the most pronounced effect of
GLP-1 treatment seems to be a blood pressure reduction,
whereas the renal effects have not been studied exten-
sively. DPP-4 inhibitors are widely used in the treatment
of diabetes in order to elevate the endogenous GLP-1
levels. In healthy humans, GLP-1 does not affect renal
hemodynamics (Skov et al. 2013; Asmar et al. 2015),
whereas there may be effects in obese subjects (Gutzwiller
et al. 2004). In both healthy and obese insulin-resistant
humans, GLP-1 induces an increase in diuresis and Na+
excretion.
How GLP-1 mediates its renal effects is not fully
understood, but several studies demonstrate that the
GLP-1 receptor is expressed in the kidney in both rodents
and humans. However, there is no consensus about the
exact location as some authors show expression in the
proximal tubules and glomeruli (Crajoinas et al. 2011),
whereas others show that it is only expressed in the renal
vasculature (Fujita et al. 2013; Pyke et al. 2014; Jensen
et al. 2015).
In this study, we investigated the expression of the
GLP-1 receptor in renal tissue from SHR along with renal
and cardiovascular effects of acute GLP-1 treatment in
SHR. Our hypothesis was that the GLP-1 receptor is
expressed in the renal vasculature and that GLP-1 would
reduce the hypertension in SHR. We predicted that
GLP-1 would induce a renal vasodilation and increase
urinary Na+ excretion. Furthermore, we speculated that the
vascular effects of GLP-1 receptor activation work through
activation of KATP channels. The different hypotheses were
tested by examining the effect of an acute intrarenal infu-
sion of GLP-1 on RBF, mean arterial blood pressure
(MAP), heart rate (HR), urinary flow rate, and Na+ and K+
excretion in vivo in anesthetized rats. The involvement of
KATP channels in the GLP-1-mediated vascular effects was
investigated in vivo and in isolated renal vessels by blocking
the KATP channels using glibenclamide.
Methods
GLP-1 receptor localization in the kidney
Immunohistochemical staining of the GLP-1
receptor
Pancreas and kidney were isolated from both SD rats
(n = 3) and SHR (n = 4) and were stored in 4%
paraformaldehyde for at least 1 week before further pro-
cessing. The tissues were embedded in paraffin and histo-
logical sections of 4 lm were cut with a microtome.
Sections were deparaffinated and rehydrated in double
distilled water. Sections were treated with 0.1% pronase
in PBS at 37°C for 10 min and rinsed in tris-buffered sal-
ine (TBS). Thereafter, sections were treated with dual
block (Dako, Glostrup, Denmark) for 5 min, washed in
TBS with 0.05% Tween 20 (TBST), blocked with avidin
(Life Technologies, MD) for 10 min, washed with TBST,
blocked with biotin for 10 min (Dako), washed with
TBST, and preincubated with 3.2 mg/mL poly-L-lysine,
3% BSA, 7% donkey serum, and 3% skimmed milk
(Dako) for 30 min. Sections were incubated overnight
with primary biotinylated GLP-1 receptor antibody
(7F382A, Novo Nordisk). Thereafter, sections were
washed three times for 10 min each in TBST followed by
treatment with Vectastain ABComplexHRP (Vectorlabs,
Herlev, Denmark) in TBS for 30 min and washed again
for three times for 10 min each. Sections were incubated
with TSA indirect (Perkin Elmer, Skovlunde, Denmark)
for 7 min, washed three times for 10 min with TBST fol-
lowed by treatment with Vectastain ABComplexHRP in
TBS for 30 min, and washed three times for 10 min with
TBST. Sections were developed with DAB (Dako), coun-
terstained with hematoxylin, rinsed in water, dehydrated,
and mounted.
In situ hybridization for the GLP-1 receptor
The paraffin-embedded pancreatic and kidney tissues
from SD rats (n = 3) and SHR (n = 4) were cut with a
microtome in histological sections of 3.5 lm. RNA
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molecules for the GLP-1 receptor were detected with
in situ hybridization using the automated Ventana RNA-
scope Dicovery platform (Advanced Cell Diagnostics,
Hayward, CA) following the manufacturer’s description.
Effects of acute GLP-1 infusion in vivo
All animal experiments were approved by the Danish
National Animal Experiments Inspectorate. Rats were
housed in groups of 2–3 rats in individually ventilated
cages under a light cycle of 12 h with ad libitum access to
normal chow and water.
Animal preparation
The experiments were performed in male SHR (n = 10)
weighing 270–310 g at the age of 12–14 weeks obtained
from Harlan Laboratories, Indianapolis, USA and nor-
motensive male SD rats (n = 19) weighing 290–340 g at
the age of 12–14 weeks obtained from Taconic, Lille
Skensved, Denmark. Anesthesia was induced with 8%
sevoflurane delivered in 35% oxygen and 65% nitrogen.
Polyethylene catheters (PE-10) were placed in the right
jugular vein for infusions and in the left carotid artery
(PE-50) for continuous measurement of the systemic
blood pressure by a Statham P23-dB pressure transducer
(Gould, Oxnard, CA). A tracheostomy was performed
and the rat was connected to and ventilated by a small
animal ventilator, tidal volume 1.7–2.1 mL depending
on body weight at a frequency of 60 breaths/min. The
rat was placed on a heating table to maintain body tem-
perature at 37°C. The final sevoflurane concentration
needed to maintain sufficient anesthesia was  2%. An
intravenous (i.v.) bolus injection of the muscle relaxant
cisatracurium besilate (Nimbex; GlaxoSmithKline,
Brøndby, Denmark) in 0.5 ml 0.9% saline was adminis-
tered and followed by continuous i.v. infusion of
0.6 mg/mL at 20 lL/min. Additional saline was given
continuously at a rate of 20 lL/min throughout the
experiment.
The left kidney was exposed after a laparotomy,
which was extended to the left flank. The left femoral
artery was catheterized (PE-10), and the catheter was
moved through the aorta into the ostium of the renal
artery in order to administer test agents directly into
the kidney, thereby minimizing systemic effects of these.
To keep the renal catheter open saline was infused at a
rate of 10 lL/min. The left ureter was catheterized (PE-
10 connected to PE-50) to ensure free urine flow. An
ultrasonic flow probe (Transonic 1PRB) was placed around
the left renal artery in order to measure RBF. The kidney
was superfused with heated saline (37°C) throughout the
experiment. Rats were allowed to equilibrate for at least
30 min after the surgical procedures before initiation of the
experiment.
The intrarenal infusion rate was increased from 10 to
144 lL/min when the test agents were administered in
order to ensure a rapid distribution. Renal arterial plasma
concentrations of the administered agents were the esti-
mated plasma concentrations, unless otherwise stated.
Concentrations were calculated assuming a hematocrit of
40% (Probst et al. 2006) and an average renal plasma
flow of 3 mL/min. The sequence of the following treat-
ments was randomized between the rats such that BSA
was not always first followed by GLP-1 etc. It was not
possible for all rats to receive all the different treatments.
However, all rats received GLP-1 administered alone.
During the experiment, urine was collected in 5 min peri-
ods. At the end of each treatment, a blood sample was
collected. EGTA (10 lL of 300 mmol/L) was added to the
blood samples to prevent coagulation. The blood samples
were centrifuged at 5500 g for 5 min, and the plasma was
kept frozen for later electrolyte measurement.
GLP-1-mediated effects in vivo in anesthetized
rats
We first tested the effect of 20 min intrarenal infusion of
vehicle (1% BSA dissolved in saline) to ensure that
observed changes in RBF and blood pressure was caused
by GLP-1 and not by the infusion itself (SD rats: n = 6,
SHR: n = 5). The acute effect of intrarenal infusion of
GLP-1 was investigated (SD rats: n = 19, SHR: n = 10).
GLP-1 at an estimated renal plasma concentration of
1 nmol/L was infused for 20 min. Urine was collected
every 5 min and a blood sample was drawn at the end of
the GLP-1 infusion.
Effects of exendin 9-39 in vivo in anesthetized
rats
The acute effect of intrarenal infusion of GLP-1 was also
investigated when GLP-1 receptors were blocked using
the GLP-1 receptor antagonist exendin 9-39 (SD rats:
n = 6, SHR: n = 6). An intrarenal infusion of exendin
9-39 at an estimated renal plasma concentration of
100 nmol/L was administered for 10 min prior to GLP-1
infusion. Exendin 9-39 infusion was continued during the
GLP-1 infusion. Urine was collected for 5 min intervals,
and a blood sample was drawn at the end.
Effects of inhibition of KATP channels in vivo in
anesthetized rats
The acute effect of intrarenal infusion of GLP-1 was
investigated after inhibition of KATP-channels using
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society
2017 | Vol. 5 | Iss. 23 | e13503
Page 3
J. Ronn et al. Acute Renal Effects of GLP-1 in Hypertension
glibenclamide, a KATP-channel inhibitor (SD rats: n = 8,
SHR: n = 6). An intrarenal infusion of glibenclamide at
an estimated renal plasma concentration of 10 lmol/L
was administered for 5 min prior to GLP-1 infusion. This
concentration of glibenclamide has previously been used
without affecting baseline RBF (Sorensen et al. 2011).
Glibenclamide was administered continuously during the
GLP-1 infusion. Urine was collected in 5 min intervals,
and a blood sample was drawn at the end.
Isometric myograph recordings
Isoflurane-anesthetized SD rats (n = 4) and SHR
(n = 5) were killed by cervical dislocation. Kidneys were
removed and placed in ice-cold dissection buffer pH
7.4 [(mmol/L): NaCl 135, KCl 5, MgCl 1, Hepes 10,
Glucose 5, CaCl2 1, Albumin 5 g/L]. Interlobar arteries
with an inner diameter of 200–400 lm and a length of
1–2 mm were isolated in ice-cold dissection buffer.
Two stainless steel wires (Ø 40 lm) were introduced
through the arterial lumen and the arteries were
mounted in a wire myograph (Model 620M; Danish
Myo Technology, Arhus, Denmark). The chamber con-
tained a 37°C PSS solution [(mmol/L): NaCl 130, KCl
4.7, KH2PO4 1.18, MgSO4 1.17, NaHCO3 14.9, EDTA
0.026, CaCl2 1.6, Glucose 5.5] gassed with 5% CO2 and
95% O2 to maintain a constant pH at 7.4. Lab
Chart (ADInstruments, Oxford, UK) was used to record
isometric tension.
After 30 min the arteries were stretched to L100, which
is the stretch that generates a force in the vessel wall cor-
responding to a transmural pressure of 100 mmHg (Mul-
vany and Halpern 1977). All experiments were performed
at 90% of L100. The viability was tested by addition of
noradrenaline (NE; 10 lmol/L) in a 60 mmol/L K+ solu-
tion pH 7.4 (KPSS; mmol/L): NaCl 74.7, KCl 60,
KH2PO4 1.18, MgSO4 1.17, NaHCO3 14.9, EDTA 0.026,
CaCl2 1.6, and Glucose 5.5).
After normalization and test of viability, the arteries
were allowed to equilibrate for 20 min. Hereafter, the
arteries were contracted with NE (1 lmol/L). When a
stable constriction was observed, GLP-1 was added cumu-
latively to the chamber (1 pM to 1 lmol/L) every 90 sec-
onds. Then, the chambers were washed with PSS.
Hereafter, the arteries were incubated with the KATP
channel inhibitor glibenclamide (30 lmol/L for SHR and
0.1 or 10 lmol/L for SD rats) for 30 min. NE (1 lmol/L)
was added and the GLP-1 dose–response curve repeated.
The chambers were washed and the arteries equilibrated
for 20 min. Hereafter, arteries from SHR were contracted
with NE (1 lmol/L) for the same time period as the
GLP-1 administration in order to serve as time control.
Due to the lack of effect of GLP-1, we tested the dilatory
responses of renal interlobar arteries from SHR by per-
forming a dose–response curve with ACh (1 nmol/L–
1 lmol/L) after preconstriction with 1 lmol/L NE.
Biochemical analysis
Plasma insulin concentrations were measured using a
modified commercial sandwich ELISA (cat. No. 10-1250-
01, Mercodia, Sweden) targeting “rat insulin” with plasma
recoveries of 90  9% as described previously (Wewer
Albrechtsen et al. 2016).
Analysis
For statistical analysis, SigmaPlot software (SyStat Soft-
ware, Chicago, IL) was used. RBF and mean arterial pres-
sure (MAP) are presented as a mean of the last 30 sec in
each time period. Renal vascular resistance (RVR) was
calculated as follows: RVR = MAP/RBF.
Urine flow was measured gravimetrically. Concentra-
tions of Na+ and K+ in urine and plasma were measured
by flame photometry (IL243 LED flame photometer,
Instrumentation Laboratory, Alleroed, Denmark).
Changes in MAP, RBF, HR, RVR, diuresis, Na+ excre-
tion, and K+ excretion within the groups were analyzed
using one-way ANOVA for repeated measurements fol-
lowed by Student–Newman–Keuls (SNK) post hoc test.
Differences between the different groups were analyzed
using one-way ANOVA followed by SNK post hoc test.
Differences between SD and SHR within same treatment
group were analyzed using two-way ANOVA followed by
SNK post hoc test. All results are given as mean  SEM.
P = 0.05 were considered significant.
Results
GLP-1 receptor localization in the kidney
Immunohistochemistry
In the islets of Langerhans in both SHR rats and SD there
was GLP-1 receptor-positive immunohistochemical stain-
ing (Fig. 1A and B). In the renal tissue from SD rats, there
were GLP-1 receptor immunoreactive cells in the vascula-
ture including the afferent arterioles and larger vessels
(Fig. 1C). In SHR, there were no GLP-1 receptor
immunoreactive cells in the renal tissue (Fig. 1D), showing
that there are no renal GLP-1 receptors expressed in SHR.
In situ hybridization for the GLP-1 receptor
There was GLP-1 receptor positive staining in the islets of
Langerhans in both SD rats and SHR (Fig. 2A and B).
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There was GLP-1 receptor-positive staining in the renal
vasculature from SD rats (Fig. 2C), whereas there was
very low or no GLP-1 receptor-positive staining in the
vasculature from SHR (Fig. 2D).
Effects of acute GLP-1 infusion in vivo
Baseline effects of BSA
The physiological parameters from SD and SHR rats
receiving BSA, GLP-1, and exendin 9-39 + GLP-1 are
shown in Tables 1 and 2 in actual values.
BSA administered alone for 20 min did not induce sig-
nificant changes in MAP in either rat strain (Fig. 3A).
BSA did induce a small significant change in RBF and
RVR in SD rats after 20 min (Fig. 3B and C) when com-
pared with baseline at time 0 min. In SHR BSA infusion
over 20 min reduced RBF and increased RVR but due to
variation these changes were not significant when
compared with baseline at time 0 min.
GLP-1-mediated effects on MAP
In both SD and SHR rats, GLP-1 mediated a small but
significant increase in MAP (102  3% and 107  6%,
respectively; P < 0.01; Fig. 3A). Compared to the increase
in SD the effect on MAP was significantly larger in SHR
after 10 min (P < 0.05). After pretreatment with exendin
9-39, there was no increase in MAP in either strain. Dur-
ing glibenclamide administration, GLP-1 still increased
MAP in both strains (SD: 103  2%; SHR: 106  2%).
Pretreatment with glibenclamide in SHR appeared to
increase MAP by itself (from 169  15 mm Hg to
180  12 mmHg), elevating the baseline value measured
before GLP-1 administration.
GLP-1-mediated effects on RBF
In SD rats, intrarenal infusion of 1 nmol/L GLP-1
increased RBF to 115  12% (P < 0.01) in normotensive
SD rats (n = 19: Fig. 3B). The GLP-1-mediated increase
A B
C D
Figure 1. Microphotographs of histological sections, hematoxylin stained, stained for GLP-1 receptor immunoreactivity in SD pancreas (A), SHR
pancreas (B), SD kidney (C), and SHR kidney (D). GLP-1 receptor immunoreactive cells were localized in the islets of Langerhans in both SD rats
(C) and SHR (D). In histological kidney sections from SD (C) there were GLP-1 receptor immunoreactive cells in the renal vasculature including
larger vessels (indicated with an arrow). In histological kidney sections from SHR (D) there were no GLP-1 receptor immunoreactive cells in the
renal vasculature (arrow). Scale bar indicates 50 lmol/L.
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in RBF was significant after 5 min and persisted until the
end of the GLP-1 infusion when compared with baseline
at time 0 min. Pretreatment with 100 nmol/L exendin
9-39 (n = 6) abolished the GLP-1-mediated effect on RBF
(Fig. 3B).
In SHR, intrarenal infusion of 1 nmol/L GLP-1
increased RBF to 117  13% (n = 10; Fig. 4; P < 0.01).
The increase was significant after 10 min infusion and
persisted until the end of the GLP-1 infusion. Pretreat-
ment with 100 nmol/L exendin 9-39 abolished the
increase in RBF (n = 6; Fig. 3B).
When the KATP channel inhibitor glibenclamide
(10 lmol/L) was administered as pretreatment, GLP-1
still mediated a significant increase in RBF to 118  15%
in SD (n = 8, results not shown) and 115  12% in SHR
(n = 6; results not shown), respectively.
GLP-1-mediated effects on RVR and HR
GLP-1 mediated a decrease in RVR in both strains (to
89  9% in SD rats (P < 0.01) and to 92  10% in SHR
(P < 0.01); Fig. 3C). After pretreatment with exendin
A B
C D
Figure 2. Microphotographs of histological sections, in situ hybridized for the GLP-1 receptor in SD rat pancreas (red dots) (A), SHR pancreas
(B), SD rat kidney (C), and SHR kidney (D). GLP-1 receptor-positive staining was located in the islets of Langerhans in both SD rats and SHR (A
and B) and in the renal vasculature (indicated with an arrow) in SD rats (C) but not in the renal vasculature (indicated with an arrow) SHR rats
(D). Scale bar indicates 50 lmol/L.
Table 1. Physiological status of Sprague–Dawley rats used for 20 min intrarenal administration of GLP-1.
Control (n = 9) BSA 20 min Control (n = 19) GLP-1 20 min Control (n = 6) GLP-1 + Ex 20 min
MAP (mmHg) 104  2 103  3 111  2 113  22 117  6 116  6
RBF (mL/min) 7.2  0.7 7.8  0.9 8.6  0.7 9.9  0.82 9.0  1.6 9.3  1.6
HR (BPM) 354  8 356  9 346  10 343  13
VU (lL/min) 12.1  1.7 19.1  2.8 30.6  1.9 76.5  10.82 27.6  2.4 53.2  18.12
UNa+ (lmol/min) 2.8  1.3 5.1  1.3 4.0  1.2 12.6  1.82 3.6  1.0 8.2  4.41
UK+(lmol/min) 2.7  0.2 2.3  0.2 3.5  0.3 3.6  0.9 2.7  0.3 2.5  0.2
Insulin (lg/L) 2.1  0.2 2.7  0.4
Values are mean  SE. HR, heart rate; BPM, beats per min; Vu: urine flow rate; UNa+, urinary sodium excretion rate; UK+, urinary potassium
excretion rate.
1
P < 0.05 versus control.
2
P < 0.01 versus control.
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9-39 no decrease in RVR was seen (Fig. 3C). Coadminis-
tration of glibenclamide abolished the decrease in RVR in
SHR due to the increasing effect on MAP, but not in the
SD rats (results not shown).
GLP-1, exendin 9-39, and glibenclamide did not alone
or in combination with one another affect HR (Tables 1
and 2).
GLP-1-mediated effects on diuresis and Na+
excretion
BSA administration for 20 min increased diuresis and
Na+ excretion slightly but significantly in SD rats, but not
in SHR (Fig. 4A and B). However, these increases were
smaller than the increases observed during administration
of GLP-1.
GLP-1 mediated a significant increase in diuresis in
both SD rats and SHR (307  41% and 194  31% in
SD and SHR, respectively, Fig. 4A). However, the diuretic
effect of GLP-1 was significantly larger in SD (P < 0.01).
Exendin 9-39 reduced the GLP-1-mediated diuresis
(251  55% and 168  22% in SD and SHR, respec-
tively, Fig. 4A). Glibenclamide seemed to augment the
GLP-1-mediated diuresis in SHR but no SD (data not
shown).
GLP-1 mediated a significant increase in urinary Na+
excretion in both strains (366  37% and 215  27%,
respectively, Fig. 4B). Again the natriuretic effect was sig-
nificantly larger in SD rats (P < 0.01). When GLP-1
receptors were blocked with exendin 9-39, the natriuretic
effect of GLP-1 was reduced significantly in SD rats
(230  52%; P < 0.05), but not in SHR (185  26%). In
both strains, the GLP-1-mediated increase in urinary Na+
excretion was maintained during cotreatment with gliben-
clamide (data not shown).
There were no GLP-1-mediated effects on the urinary
K+ excretion in any of the groups (Table 1 and 2).
GLP-1-mediated effects on insulin release
GLP-1 mediated an increase in plasma insulin after
20 min which was only significant in SHR rats (Tables 1
and 2).
GLP-1-mediated effects on renal arteries
ex vivo
Isometric myograph recordings
In renal interlobar arteries from SD rats, GLP-1 (1 pM to
1 lmol/L) had a significant vasodilatory effect at
100 nmol/L and 1 lmol/L (Fig. 5A; P < 0.01). Pretreat-
ment with 0.1 lmol/L or 10 lmol/L glibenclamide did
not reduce the vasodilatory effect of GLP-1 (Fig. 5A). In
interlobar arteries from SHR, GLP-1 did not affect the
vascular tone elicited by 1 lmol/L NE (Fig. 5B). The
arteries lost approximately 5% of their initial NE-induced
tone over time (Fig. 5B). Glibenclamide (30 lmol/L) had
no effect on vascular tone in SHR either (Fig. 5B).
To verify that the renal SHR arteries responded nor-
mally, the effect of endothelial activation using ACh
(1 nmol/L–1 lmol/L) was also tested. At 1 lmol/L ACh
the NE induced constriction was reduced by 49  5%
(results not shown).
Discussion
This study demonstrates that intrarenal infusion of GLP-1
in normotensive SD rats and hypertensive SHR increases
RBF, MAP, diuresis, and Na+ excretion. However, the
diuretic and natriuretic effect in SHR was attenuated,
whereas the effect on MAP and plasma insulin concentra-
tions was slightly increased. The effects of GLP-1 on RBF
and MAP in SD rats and SHR were abolished by exendin
Table 2. Physiological status of SHR rats used for 20 min intrarenal administration of GLP-1.
Control (n = 5) BSA 20 min Control (n = 10) GLP-1 20 min Control (n = 6) GLP-1 + Ex 20 min
MAP (mmHg) 158  9 159  8 167  9 178  101 167  5 167  5
RBF (mL/min) 4.1  0.4 3.9  0.5 4.4  0.7 5.1  0.81 4.4  0.4 4.6  0.5
HR (BPM) 288  6 287  6 286  7 288  6
VU (lL/min) 10.1  2.3 13.3  3.2 13.9  1.9 24.8  7.81 13.0  3.0 19.5  3.11
UNa+ (lmol/min) 1.8  0.6 2.5  0.8 2.0  0.5 4.2  1.31 2.6  0.9 3.7  0.91
UK+(lmol/min) 1.2  0.2 1.1  0.2 1.3  0.1 1.3  0.1 1.3  0.2 1.4  0.2
Insulin (lg/L) 1.8  0.2 4.2  0.82
Values are mean  SE.
HR, heart rate; BPM, beats per min; Vu, urine flow rate; UNa+, urinary sodium excretion rate; UK+, urinary potassium excretion rate.
1P < 0.01 versus control.
2P < 0.05 versus BSA.
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Figure 3. Changes in mean arterial pressure (MAP; A), renal blood flow (RBF; B), and renal vascular resistance (RVR; C) in SD and SHR rats
after intrarenal infusion of 1% BSA (n = 9 and n = 5), 1 nmol/L GLP-1 (n = 19 and n = 10), GLP-1 and exendin 9-39 (100 nmol/L; n = 6 and
n = 6). Values are normalized means  SE. *P < 0.05 versus time 0; **P < 0.01 versus time 0; #P < 0.05 SD versus SHR within same treatment
group; ##P < 0.01 SD versus SHR within same treatment group.
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9-39 showing that these effects are receptor specific. The
diuretic and natriuretic effects were only partly reduced
by exendin 9-39 indicating that these effects are at least
partly caused by a secondary mechanism. Immunohisto-
chemical staining and in situ hybridization for the GLP-1
receptor in kidneys from SHR showed no or very low
expression of the GLP-1 receptor. The GLP-1 receptor
was widely expressed in the entire renal vascular tree in
SD rats with no expression in the tubular system. These
results suggest that the renal effects of GLP-1 in SHR do
not rely on the presence of renal GLP-1 receptors. There-
fore, it seems likely that the GLP-1-mediated effects in
SHR are mediated via extrarenal GLP-1 receptors, for
example GLP-1 receptors in organs responsible for regula-
tion of insulin or ANP or possibly by an alternative renal
receptor.
We have previously demonstrated GLP-1 receptors in
the renal vasculature of normotensive rats (Jensen et al.
2015). Liu et al. (2015) reported a reduced expression of
GLP-1 receptors in renal arteries from SHR compared to
WKY and also in human renal arteries from hypertensive
patients based on immunostainings. Quantification based
on immunostaining can, however, be extremely difficult.
We found no or very low GLP-1 receptor expression in
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Figure 4. Changes in urine and sodium excretion in SD and SHR rats after intrarenal infusion of 1% BSA (n = 6 and n = 5), 1 nmol/L GLP-1
(n = 19 and n = 10), GLP-1 and exendin 9-39 (100 nmol/L; n = 6 and n = 6). *P < 0.05 versus time 0; **P < 0.01 versus time 0; #P < 0.05 SD
versus SHR within same treatment group; ##P < 0.01 SD versus SHR within same treatment group.
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the kidney from SHR based on immunohistochemical
stainings and in situ hybridization. Savignano et al.
(2017) also found a significantly reduced expression of
GLP-1 receptors in renal arteries from SHR measured by
RT-PCR . In accordance with this, we observed no GLP-
1-mediated vasodilatation in isolated interlobar arteries
from SHR rats, whereas renal arteries from SD rats
showed a GLP-1-mediated vasodilatation. Similar results
were found by Savignano et al. (2017) and Liu et al.
(2015) who also showed that inhibition of protein kinase
C (PKC) restored the GLP-1 induced vasodilation and
the expression of the GLP-1 receptor in renal vessels from
SHR. These observations suggest that renal effects of
GLP-1 in SHR are mainly mediated via mechanisms sec-
ondary to nonrenal GLP-1 receptor activation. These sec-
ondary mechanisms could be increased levels of insulin
or atrial natriuretic peptide (ANP) both shown to affect
renal vascular and tubular function (Kim et al. 2013;
Artunc et al. 2016). Indeed, we did find a significant
increase in plasma insulin concentrations in SHR after
20 min of intrarenal GLP-1 infusion to substantiate this.
Whether the lack of renal GLP-1 receptors in SHR is a
cause or a consequence of hypertension remains to be
established.
In this study, there was a GLP-1 receptor-dependent
increase in MAP in both SD rats and SHR which was sig-
nificant after 5 min. Jackson et al. (2015) demonstrated
that 3 weeks administration of the DPP-4-inhibitor sita-
gliptin increased MAP in SHR but not in normotensive
Wistar–Kyoto rats . However, using a higher concentra-
tion of sitagliptin Liu et al. (2012) found a reduction in
MAP combined with an increase in RBF . It seems that
the GLP-1-mediated effect on MAP may dependent on
the concentration used. In other hypertensive models
Figure 5. Dose–response curve of increasing concentrations of GLP-1 in untreated renal interlobar arteries and arteries pretreated with
glibenclamide. Arteries were preconstricted with 1 lmol/L NE. Arteries were isolated from (A) SD rats (n = 4) and B) SHR (n = 5). Time control
curve for SHR is included for reference. #, P < 0.01 versus NE.
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such as Angiotensin II induced hypertensive rats (Hirata
et al. 2009) and in hypertensive Dahl salt-sensitive rat
(Yu et al. 2003), GLP-1 agonists have been shown to
reduce MAP. In this study, the treatment is acute using
native GLP-1. It is possible that a longer treatment period
or another hypertensive model would have revealed a
reduced MAP. In a human study acute treatment with
liraglutide significantly increased diastolic and systolic
blood pressure in patients with T2DM (Skov et al. 2016).
In vivo we found a GLP-1 receptor-dependent increase
in RBF in both SD rats and SHR as the response in both
strains was abolished by exendin 9-39. This is in contrast
to the findings of Savignano et al. (2017) who found an
increase in RBF after a 30 min i.v. infusion of GLP-1 in
normotensive Wistar rats but not in SHR . However, they
only measured RBF at the end of the infusion, whereas
we measure continuously. Also, our infusion is directly
into the renal artery which could result in a higher renal
concentration of GLP-1. Possibly the same mechanisms
are not responsible for the GLP-1-mediated vasodilatation
in vivo of the renal arteries in normo- and hypertensive
rats. The GLP-1-mediated increase in RBF in SHR could
possibly be explained by a GLP-1-mediated increase in
insulin which we also show here. Even though the SHR
has been shown to be insulin resistant, insulin still elicits
vasodilation in several vascular beds (Potenza et al. 2005).
At high concentration insulin also induces an increase in
MAP in SHR (Pitre et al. 1996). Several studies have
shown a renal vasodilating effect of insulin (Cohen et al.
1989; Stenvinkel et al. 1995; Qadir and Porter 1996) most
likely mediated via release of NO (Hayashi et al. 1997;
Molinari et al. 2001). The insulin-mediated renal vasodi-
lation has been found to be associated with reduced tubu-
lar Na+ reabsorption. Insulin infusion combined with a
slight volume load reduced both proximal and distal
reabsorption of Na+ and water in healthy humans (Nor-
gaard et al. 1991). In our experimental set-up, the rats
receive 144 lL saline pr. min. Thus, the combined effect
of a GLP-1-mediated insulin release and the volume load
could account for the renal vasodilation and the increased
diuresis and natriuresis in vivo despite the lack of GLP-1
receptor expression in renal tissue in SHR. However,
other studies have shown that the renal vasodilatory effect
of insulin is reduced in SHR compared to normotensive
rats (Santure et al. 2000).
In humans, genetic variations in the GLP-1 receptor
have been shown to affect the efficacy of hypoglycemic
agents (de Luis et al. 2015; Han et al. 2016). It is possible
that the GLP-1 receptor expressed in SHR is a variant.
However, the variations found in humans are one amino
acid substitutions and most likely these variants would
respond to the staining methods used in this study.
Another possible explanation for the GLP-1-mediated
renal effects in SHR could be a GLP-1-mediated increase
in ANP (Kim et al. 2013), which is natriuretic in anes-
thetized rats (de Bold et al. 1981) and has a renal vasodi-
lating effect (Marin-Grez et al. 1986). The GLP-1-induced
increase in ANP has not been demonstrated in humans
(Asmar et al. 2015).
As previously shown in normotensive rats, GLP-1
reduces renal vascular resistance significantly in both SD
rats and SHR. Interestingly the increase in RBF is com-
bined with an increase in MAP. How this GLP-1-
mediated increase in MAP is elicited is still unknown but
we found no significant changes in HR to account for
this, speaking against an involvement of the sympathetic
nervous system. However, GLP-1 has also been shown to
increase the release of vasopressin (Bojanowska and
Stempniak 2000) concurrent with increases in blood
pressure. Pretreatment with a vasopressin receptor (V1)
antagonist inhibited the increase in blood pressure (Isbil-
Buyukcoskun and Gulec 2004). V1 is primarily expressed
on vascular smooth muscle cells and mediates vasocon-
striction (Katusic et al. 1984).
Intrarenal infusion of 1 nmol/L GLP-1 significantly
increased RBF and MAP in both rat strains. This was fol-
lowed by significant increases in diuresis and urinary Na+
excretion. In SHR, the natriuretic and diuretic effect was
reduced compared to SD rats and is most likely driven by
effects elicited by extrarenal GLP-1 receptors. As with the
changes in RBF, both increases in insulin (Norgaard et al.
1991) and ANP (Kim et al. 2013) could account for this.
Exendin 9-39 abolished the effects of GLP-1 on RBF
and MAP in both strains, but the diuresis and Na+ excre-
tion still increased during coadministration of exendin
9-39. This suggests that the increase in diuresis and Na+
excretion is not driven by the hemodynamic changes
induces by GLP-1 alone. A possible explanation may be
GLP-1-mediated release of vasopressin. Studies show an
increased circulating concentration of vasopressin in rats
after GLP-1 injection (Bojanowska and Stempniak 2000).
Vasopressin has been show to increase natriuresis in high
concentrations via the V1a receptor (Perucca et al. 2008).
The combined infusion of a V1a receptor agonist and
GLP-1 in rats had a cumulative effect on Na+ excretion
(Kutina et al. 2016). Furthermore, GLP-1 was able to
increase free water clearance even during blockade of the
V2 receptor (Kutina et al. 2013).
Differences in activity of the sodium-hydrogen antipor-
ter 3 (NHE3) in the proximal tubule could explain the
reduced effect of GLP-1 on diuresis and urinary Na+
excretion in SHR. NHE3 activity is regulated by phospho-
rylation by PKA (Cabado et al. 1996). Increased phospho-
rylation reduces NHE3 activity in proximal tubules in rats
(Kocinsky et al. 2005). It has been demonstrated that
GLP-1 increases urinary excretion of cAMP in
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normotensive rats (Crajoinas et al. 2011). Possibly the
increased cAMP production after GLP-1 treatment leads
to reduced NHE3 activity and thereby increased diuresis
and urinary Na+ excretion. Inhibition of GLP-1 receptors
using exendin 9-39 reduced NHE3 phosphorylation,
increased NHE3 activity and resulted in decreased diuresis
and urinary Na+ excretion (Farah et al. 2015) as also
shown in our experiments. Here, we report a lack of renal
GLP-1 receptor expression in SHR and it may be specu-
lated that the generation of cAMP and thus activation of
PKA is significantly reduced in SHR. This in turn would
increase NHE3 activity to reduce sodium excretion. How-
ever, we were not able to fully inhibit the diuretic and
natriuretic effect of GLP-1 using exendin 9-39 and thus
the diuretic and natriuretic effect of GLP-1 seems very
complex and not fully elucidated.
A previous study has suggested that the vasodilating
effect seen after GLP-1 receptor activation is caused by
opening of vascular KATP channels (Green et al. 2008).
To test this, we pretreated rats with the putative KATP
inhibitor glibenclamide in a concentration previously
shown not to affect RBF in vivo (Sorensen et al. 2011),
but to be effective in vitro (Engbersen et al. 2012). Nei-
ther in normotensive nor in hypertensive rats, did gliben-
clamide reduce the effects of GLP-1. As glibenclamide
also increases insulin release (Efendic et al. 1979) it is
possible that the observed effect in these experiments is
caused by an additional increase in insulin release.
Another possibility is that glibenclamide in high concen-
trations acts as an opener of KATP channels. However,
voltage-gated potassium channels (KV7) have also been
suggested to be activated by GLP-1 receptor activation
(Selley et al. 2014). These channels have been shown to
be expressed in renal vessels from rats and to participate
in maintaining baseline RBF (Salomonsson et al. 2015).
In summary, we show that kidneys from hypertensive
SHR rats lack expression of GLP-1 receptors. This leads to
an absence of renal vasodilation in isolated interlobar arter-
ies from SHR. However, intrarenal infusion of GLP-1 elicits
changes in RBF comparable to the changes observed in nor-
motensive rats. These changes could be mediated by insulin
or vasopressin. The GLP-1-induced increase in urinary flow
rate and sodium excretion is reduced in SHR possibly due
to reduced vasopressin release or reduced NHE3 activity.
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